NCT06664996View on ClinicalTrials.gov

Sintilimab Combined SBRT As Neoadjuvant Therapy for Resectable HCC with PVTT

PHASE2RecruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

October 15, 2024

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2026

Conditions
Hepatocellular Carcinoma (HCC)
Interventions
RADIATION

stereotactic body radiation therapy (SBRT)

SBRT will be administered on days 1, 3, and 5 at a dose of 8 Gy per fraction, totaling 3 fractions.

DRUG

Sintilimab (approved)

patients will receive a first dose of sintilimab at 200 mg on day 1, followed by a second dose of 200 mg on day 22 (week 4, ±3 days).

Trial Locations (1)

610041

RECRUITING

West China Hospital, Chengdu

All Listed Sponsors
lead

West China Hospital

OTHER